Výsledky vyhledávání - "Kristy J. Gotink"

Akademický článek

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer

Autor: Kaamar Azijli, Kristy J Gotink, Henk M.W Verheul

Publikováno v: Journal of Kidney Cancer and VHL, Vol 2, Iss 4 (2016)

Renal cell carcinoma (RCC) is a highly vascularized tumor type, which is often associated with inactivated mutations in the von Hippel-Lindau gene that drives proangiogenic signaling pathways. As such, new therapies for the treatment of RCC have larg

Externí odkaz: https://doaj.org/article/449c7c4543cd476bb0338d0f89ea5440

Zobrazit plný text záznamu

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature

Autor: Godefridus J. Peters, Arjan W. Griffioen, Kiersten Marie Miles, Richard R. de Haas, Remi Adelaiye, Roberto Pili, Henk J. Broxterman, Henk L. Dekker, Henk M.W. Verheul, Richard J. Honeywell, Kristy J. Gotink

Publikováno v: Oncoscience

Acquired resistance to anti-angiogenic tyrosine kinase inhibitors is an important clinical problem in treating various cancers. To what extent acquired resistance is determined by microenvironmental host-factors or by tumor cells directly is unknown.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b0feb8c69a0339307f24b978ec494a0
https://doi.org/10.18632/oncoscience.106

Zobrazit plný text záznamu

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer

Autor: Johannes C. van der Mijn, Kaamar Azijli, Kristy J. Gotink, Henk L. Dekker, Mariette Labots, Connie R. Jimenez, Sander R. Piersma, Charlotte M. Huijts, Henk M.W. Verheul

Publikováno v: Labots, M, Gotink, K J, Dekker, H, Azijli, K, van der Mijn, J C, Huijts, C M, Piersma, S R, Jiménez, C R & Verheul, H M W 2016, ' Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer ', Experimental & Molecular Medicine, vol. 48, no. 12, pp. e279 . https://doi.org/10.1038/emm.2016.114
Experimental & Molecular Medicine
Experimental & Molecular Medicine, 48(12). Korean Society of Med. Biochemistry and Mol. Biology

Personalized cancer medicine aims to accurately predict the response of individual patients to targeted therapies, including tyrosine kinase inhibitors (TKIs). Clinical implementation of this concept requires a robust selection tool. Here, using both

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b1aecbf1d073a48007a8679ed22d7d
https://research.vumc.nl/en/publications/2b0b9cff-3370-4e7f-bfca-3c69dbb7d6a1

Zobrazit plný text záznamu

Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance

Autor: Henk J. Broxterman, Arjan W. Griffioen, Henk L. Dekker, Mariette Labots, Roberto Pili, Gerrit Jansen, Godefridus J. Peters, Michelle A. Rudek, Richard J. Honeywell, René J. P. Musters, Laurens V. Beerepoot, Henk M.W. Verheul, Richard R. de Haas, Yehuda G. Assaraf, Kristy J. Gotink

Publikováno v: Clinical Cancer Research, 17(23), 7337-7346. American Association for Cancer Research Inc.
Gotink, K J, Broxterman, H J, Labots, M, de Haas, R R, Dekker, H, Honeywell, R J, Rudek, M A, Beerepoot, L V, Musters, R J P, Jansen, G, Griffioen, A W, Assaraf, Y G, Pili, R, Peters, G J & Verheul, H M W 2011, ' Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance ', Clinical Cancer Research, vol. 17, no. 23, pp. 7337-7346 . https://doi.org/10.1158/1078-0432.CCR-11-1667

Purpose: Resistance to antiangiogenic tyrosine kinase inhibitors such as sunitinib is an important clinical problem, but its underlying mechanisms are largely unknown. We analyzed tumor sunitinib levels in mice and patients and studied sensitivity an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed7bc676f82f57ce4d126b733e71dbf9
https://doi.org/10.1158/1078-0432.ccr-11-1667

Zobrazit plný text záznamu

Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib

Autor: Kristy J. Gotink, Henk M.W. Verheul, Henk J. Broxterman

Publikováno v: Drug Resistance Updates, 12(4-5), 114-126. Churchill Livingstone
Broxterman, H J, Gotink, K J & Verheul, H M W 2009, ' Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib ', Drug Resistance Updates, vol. 12, no. 4-5, pp. 114-126 . https://doi.org/10.1016/j.drup.2009.07.001

Multiple molecular, cellular, micro-environmental and systemic causes of anticancer drug resistance have been identified during the last 25 years. At the same time, genome-wide analysis of human tumor tissues has made it possible in principle to asse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f62fad651ee66b7452a62bf30c538ad
https://doi.org/10.1016/j.drup.2009.07.001

Zobrazit plný text záznamu

Abstract 1621: Short-time exposure to high concentrations of sunitinib causes tumor cell death

Autor: Henk L. Dekker, Henk M.W. Verheul, Mariette Labots, Jens Voortman, Maria Rovithi, Kristy J. Gotink, Dennis Poel, Henk J. Broxterman

Publikováno v: Cancer Research. American Association for Cancer Research Inc.
Voortman, J 2013, ' Abstract 1621: Short-time exposure to high concentrations of sunitinib causes tumor cell death. ', Cancer Research . https://doi.org/10.1158/1538-7445.AM2013-1621

Background: Sunitinib, although initially developed as an antiangiogenic agent, has been shown to exert direct anti-tumor effects. Previously we demonstrated that sunitinib inhibits proliferation of various tumor cell lines in a dose-dependent manner

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fae02157e6ae73663374170120a84a40
https://research.vumc.nl/en/publications/8d28f63e-8401-4c49-9ca3-af873bf780cf

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání